131 related articles for article (PubMed ID: 19144092)
1. Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients.
Toki D; Ishida H; Horita S; Setoguchi K; Yamaguchi Y; Tanabe K
Transpl Int; 2009 Apr; 22(4):447-54. PubMed ID: 19144092
[TBL] [Abstract][Full Text] [Related]
2. Experiences and problems pre-operative anti-CD20 monoclonal antibody infusion therapy with splenectomy and plasma exchange for ABO-incompatible living-donor liver transplantation.
Usui M; Isaji S; Mizuno S; Sakurai H; Uemoto S
Clin Transplant; 2007; 21(1):24-31. PubMed ID: 17302588
[TBL] [Abstract][Full Text] [Related]
3. B-cell surface marker analysis for improvement of rituximab prophylaxis in ABO-incompatible adult living donor liver transplantation.
Egawa H; Ohmori K; Haga H; Tsuji H; Yurugi K; Miyagawa-Hayashino A; Oike F; Fukuda A; Yoshizawa J; Takada Y; Tanaka K; Maekawa T; Ozawa K; Uemoto S
Liver Transpl; 2007 Apr; 13(4):579-88. PubMed ID: 17394164
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of rituximab in kidney transplantation.
Genberg H; Hansson A; Wernerson A; Wennberg L; Tydén G
Transplantation; 2007 Dec; 84(12 Suppl):S33-6. PubMed ID: 18162986
[TBL] [Abstract][Full Text] [Related]
5. New protocol of immunosuppression for liver transplantation across ABO barrier: the use of Rituximab, hepatic arterial infusion, and preservation of spleen.
Yoshizawa A; Sakamoto S; Ogawa K; Kasahara M; Uryuhara K; Oike F; Ueda M; Takada Y; Egawa H; Tanaka K
Transplant Proc; 2005 May; 37(4):1718-9. PubMed ID: 15919443
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens.
Tanabe K; Ishida H; Shimizu T; Omoto K; Shirakawa H; Tokumoto T
Contrib Nephrol; 2009; 162():61-74. PubMed ID: 19001814
[TBL] [Abstract][Full Text] [Related]
7. A novel approach to successful ABO-incompatible high-titer renal transplantation.
Uchida J; Iwai T; Kato M; Machida Y; Naganuma T; Kumada N; Yoshimura R; Kawashima H; Kim T; Nakatani T
Transplant Proc; 2008 Sep; 40(7):2285-8. PubMed ID: 18790213
[TBL] [Abstract][Full Text] [Related]
8. Determination of rituximab dose according to immunologic risk in ABO-incompatible kidney transplantation.
Chung BH; Hong YA; Sun IO; Piao SG; Kim JI; Moon IS; Choi BS; Park CW; Kim YS; Yang CW
Ren Fail; 2012; 34(8):974-9. PubMed ID: 22817654
[TBL] [Abstract][Full Text] [Related]
9. ABO blood type incompatible kidney transplantation without splenectomy prepared with plasma exchange and rituximab.
Chikaraishi T; Sasaki H; Tsutsumi H; Miyano S; Nakazawa R; Nakano T; Kitajima K; Kudo H; Takahashi T; Sato Y; Kimura K
Transplant Proc; 2008 Dec; 40(10):3445-7. PubMed ID: 19100409
[TBL] [Abstract][Full Text] [Related]
10. Double-filtration plasmapheresis.
Tanabe K
Transplantation; 2007 Dec; 84(12 Suppl):S30-2. PubMed ID: 18162985
[TBL] [Abstract][Full Text] [Related]
11. ABO-incompatible kidney transplantation and rituximab.
Tydén G; Kumlien G; Genberg H; Sandberg J; Lundgren T; Fehrman I
Transplant Proc; 2005 Oct; 37(8):3286-7. PubMed ID: 16298574
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus infection following renal transplantation in patients administered low-dose rituximab induction therapy.
Nishida H; Ishida H; Tanaka T; Amano H; Omoto K; Shirakawa H; Shimizu T; Iida S; Toki D; Yamaguchi Y; Tanabe K
Transpl Int; 2009 Oct; 22(10):961-9. PubMed ID: 19619177
[TBL] [Abstract][Full Text] [Related]
13. Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection.
Steinmetz OM; Lange-Hüsken F; Turner JE; Vernauer A; Helmchen U; Stahl RA; Thaiss F; Panzer U
Transplantation; 2007 Oct; 84(7):842-50. PubMed ID: 17984836
[TBL] [Abstract][Full Text] [Related]
14. In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody.
Sidner RA; Book BK; Agarwal A; Bearden CM; Vieira CA; Pescovitz MD
Hum Antibodies; 2004; 13(3):55-62. PubMed ID: 15598985
[TBL] [Abstract][Full Text] [Related]
15. The Stockholm experience with ABO-incompatible kidney transplantations without splenectomy.
Tydén G; Kumlien G; Genberg H; Sandberg J; Sedigh A; Lundgren T; Gjertsen H; Fehrman I
Xenotransplantation; 2006 Mar; 13(2):105-7. PubMed ID: 16623801
[TBL] [Abstract][Full Text] [Related]
16. Reconstitution of peripheral allospecific CD19+ B-cell subsets after B-lymphocyte depletion therapy in renal transplant patients.
Kopchaliiska D; Zachary AA; Montgomery RA; Leffell MS
Transplantation; 2009 May; 87(9):1394-401. PubMed ID: 19424042
[TBL] [Abstract][Full Text] [Related]
17. Impact of low-dose rituximab on splenic B cells: evidence for the shaving reaction.
Taylor RP; Lindorfer MA
Transpl Int; 2010 Jan; 23(1):116-7. PubMed ID: 19624496
[No Abstract] [Full Text] [Related]
18. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy.
Cravedi P; Ruggenenti P; Sghirlanzoni MC; Remuzzi G
Clin J Am Soc Nephrol; 2007 Sep; 2(5):932-7. PubMed ID: 17702725
[TBL] [Abstract][Full Text] [Related]
19. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy.
Thaunat O; Patey N; Gautreau C; Lechaton S; Fremeaux-Bacchi V; Dieu-Nosjean MC; Cassuto-Viguier E; Legendre C; Delahousse M; Lang P; Michel JB; Nicoletti A
Transplantation; 2008 Jun; 85(11):1648-53. PubMed ID: 18551073
[TBL] [Abstract][Full Text] [Related]
20. Pronase treatment facilitates alloantibody flow cytometric and cytotoxic crossmatching in the presence of rituximab.
Bearden CM; Agarwal A; Book BK; Sidner RA; Gebel HM; Bray RA; Pescovitz MD
Hum Immunol; 2004 Aug; 65(8):803-9. PubMed ID: 15336781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
